References
1. Maniadakis N, Toth E, Schiff M, et al. A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences. Adv Ther . 2018;35(9):1333-1355. doi:10.1007/s12325-018-0759-0
2. Jacobs P, Bissonnette R, Guenther LC. Socioeconomic burden of immune-mediated inflammatory diseases - Focusing on work productivity and disability. J Rheumatol . 2011;38(SUPPL. 88):55-61. doi:10.3899/jrheum.110901
3. Tsao NW, Lynd LD, Sayre EC, Sadatsafavi M, Hanley G, De Vera MA. Use of biologics during pregnancy and risk of serious infections in the mother and baby: A Canadian population-based cohort study. BMJ Open . 2019;9(2):1-9. doi:10.1136/bmjopen-2018-023714
4. Bröms G, Kieler H, Ekbom A, et al. Anti-TNF treatment during pregnancy and birth outcomes: Apopulation-based study from Denmark, Finland, and Sweden. Pharmacoepidemiol Drug Saf . 2020;(September 2019):1-12. doi:10.1002/pds.4930
5. Kvien TK, Uhlig T, Ødegård S, Heiberg MS. Epidemiological aspects of rheumatoid arthritis: The sex ratio. Ann N Y Acad Sci . 2006;1069:212-222. doi:10.1196/annals.1351.019
6. De Lorenzo R, Ramirez GA, Punzo D, et al. Neonatal outcomes of children born to mothers on biological agents during pregnancy: State of the art and perspectives. Pharmacol Res . 2020;152(September 2019):104583. doi:10.1016/j.phrs.2019.104583
7. Yockey LJ, Iwasaki A. Interferons and Proinflammatory Cytokines in Pregnancy and Fetal Development. Immunity . 2018;49(3):397-412. doi:10.1016/j.immuni.2018.07.017
8. Cornish J, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut . 2007;56(6):830-837. doi:10.1136/gut.2006.108324
9. Genest G, Spitzer KA, Laskin CA. Maternal and fetal outcomes in a cohort of patients exposed to tumor necrosis factor inhibitors throughout pregnancy. J Rheumatol . 2018;45(8):1109-1115. doi:10.3899/jrheum.171152
10. Selinger CP, Nelson-Piercy C, Fraser A, et al. IBD in pregnancy: Recent advances, practical management. Frontline Gastroenterol . Published online 2020:1-11. doi:10.1136/flgastro-2019-101371
11. Tsao NW, Rebic N, Lynd LD, De Vera MA. Maternal and neonatal outcomes associated with biologic exposure before and during pregnancy in women with inflammatory systemic diseases: a systematic review and meta-analysis of observational studies. Rheumatology . 2020;59(8):1808-1817. doi:10.1093/rheumatology/keaa064
12. Komaki F, Komaki Y, Micic D, Ido A, Sakuraba A. Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor-α use in females with immune mediated diseases; a systematic review and meta-analysis. J Autoimmun . 2017;76:38-52. doi:10.1016/j.jaut.2016.11.004
13. NHS Centre for Reviews and Dissemination. Systematic reviews: CRD’s guidance for undertaking reviews in health care. Univ York York, UK, . Published online 2009. https://www.york.ac.uk/media/crd/Systematic_Reviews.pdf
14. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.PLoS Med . 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097
15. McDonald SD, Han Z, Mulla S, Murphy KE, Beyene J, Ohlsson A. Preterm birth and low birth weight among in vitro fertilization singletons: A systematic review and meta-analyses. Eur J Obstet Gynecol Reprod Biol . 2009;146(2):138-148. doi:10.1016/j.ejogrb.2009.05.035
16. Nyaga VN, Arbyn M, Aerts M. Metaprop: A Stata command to perform meta-analysis of binomial data. Arch Public Heal . 2014;72(1):1-10. doi:10.1186/2049-3258-72-39
17. Carman WJ, Accortt NA, Anthony MS, Iles J, Enger C. Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use. Pharmacoepidemiol Drug Saf . 2017;26(9):1109-1118. doi:10.1002/pds.4261
18. Clowse MEB, Scheuerle AE, Chambers C, et al. Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database. Arthritis Rheumatol . 2018;70(9):1399-1407. doi:10.1002/art.40508
19. Chaparro M, Verreth A, Lobaton T, et al. Long-term safety of in utero exposure to anti-TNFα drugs for the treatment of inflammatory bowel disease: Results from the multicenter European TEDDY study.Am J Gastroenterol . 2018;113(3):396-403. doi:10.1038/ajg.2017.501
20. Mahadevan U, Long MD, Kane S V., et al. Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease. Gastroenterology . 2021;160(4):1131-1139. doi:10.1053/j.gastro.2020.11.038
21. Nielsen OH, Gubatan JM, Juhl CB, Streett SE, Maxwell C. Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol . Published online 2021. doi:10.1016/j.cgh.2020.09.021
22. Chawanpaiboon S, Vogel JP, Moller AB, et al. Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis. Lancet Glob Heal . 2019;7(1):e37-e46. doi:10.1016/S2214-109X(18)30451-0
23. Geldhof A, Slater J, Clark M, Chandran U, Coppola D. Exposure to In iximab During Pregnancy : Post-Marketing Experience. 2019;(0123456789).
24. Luu M, Benzenine E, Doret M, et al. Continuous Anti-TNFα Use Throughout Pregnancy: Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION). Am J Gastroenterol . 2018;113(11):1669-1677. doi:10.1038/s41395-018-0176-7
25. De Lima A, Zelinkova Z, Van Der Ent C, Steegers EAP, Van Der Woude CJ. Tailored anti-TNF therapy during pregnancy in patients with IBD: Maternal and fetal safety. Gut . 2016;65(8):1261-1268. doi:10.1136/gutjnl-2015-309321
26. Kanis SL, Modderman S, Escher JC, et al. Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life. Gut . 2021;70(7):1266-1274. doi:10.1136/gutjnl-2019-319129
27. U. M, D.C. B, M.C. D, et al. Pregnancy outcomes in the tofacitinib ulcerative colitis octave studies. Am J Gastroenterol . 2017;112:S410-S411. doi:10.1038/ajg.2017.303
28. Moens A, van der Woude CJ, Julsgaard M, et al. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study.Aliment Pharmacol Ther . 2020;51(1):129-138. doi:10.1111/apt.15539
29. Tsao NW, Sayre EC, Hanley G, et al. Risk of preterm delivery and small-for-gestational-age births in women with autoimmune disease using biologics before or during pregnancy: A population-based cohort study.Ann Rheum Dis . 2018;77(6):869-874. doi:10.1136/annrheumdis-2018-213023
30. Chambers CD, Johnson DL, Xu R, et al. Birth outcomes in women who have taken adalimumab in pregnancy: A prospective cohort study.PLoS One . 2019;14(10):1-17. doi:10.1371/journal.pone.0223603
31. Kawai Y, Tsuchiya T, Aoki S. Pregnancy Outcomes of Patients Exposed to Adalimumab in Japan. Dig Dis . 2019;37(2):123-130. doi:10.1159/000493462
32. Lichtenstein GR, Feagan BG, Mahadevan U, et al. Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report.Am J Gastroenterol . 2018;113(11):1678-1688. doi:10.1038/s41395-018-0202-9
33. Julsgaard M, Hvas CL, Gearry RB, et al. Anti-TNF Therapy in Pregnant Women with Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes. Inflamm Bowel Dis . 2020;26(1):93-102. doi:10.1093/ibd/izz110